FIELD: chemistry.
SUBSTANCE: invention relates to versions of an improved method of producing a diazabicyclooctane derivative of formula (VII), including a compound (VII-1). Invention also relates to a method of producing intermediate products IV and VI. Compound (VII) is an inhibitor of β-lactamase and can be used as an antimicrobial agent.
[Chemical formula 80],
VII,
for example, compounds
[Chemical formula 101]
.
Method of producing a compound of formula (VII) involves reacting a compound of formula (III)
[Chemical formula 76]
[Chemical formula 77]
,
where R1 is 2,5-dioxopyrrolidin-1-yl, 1,3-dioxo-3a,4,7,7a-tetrahydro-1H-isoindole-2(3H)-yl, 1,3-dioxohexahydro-1H-isoindole-2(3H)-yl or 3,5-dioxo-4-azatricyclo[5.2.1.02.6]dec-8-en-4-yl; and OBn is benzyloxy; with a compound: R3ONH2, to obtain a compound of formula (IV), where R3 is C1-6alkyl or heterocyclyl, R3 can be modified 0–5 R4; R4 can be successively substituted, wherein R4 is C1-6alkyl, heterocyclyl, R5(R6)N- or protective group; R5 and R6, each independently represents hydrogen or C1-6alkyl or together form heterocyclyl; in addition, when R3 is C1-6alkyl, and R4, which modifies R3, namely R5 or R6, contained in R5(R6)N-, are C1-6alkyl, R3 and R5 or R6 can together form 3–7-member saturated ring; and OBn is benzyloxy; treating compound IV with a palladium-carbon catalyst in a hydrogen atmosphere, with simultaneous or sequential sulphation reaction using a sulphur trioxide-trimethylamine complex in the presence of a catalytic amount of a base in an aqueous solvent based on alcohol and treatment with tetrabutylammonium hydrogen sulphate to obtain a compound of formula (VI),
[Chemical formula 78]
[Chemical formula 79]
where R3 is C1-6alkyl or heterocyclyl, R3 can be modified 0–5 R4; R4 can be successively substituted, wherein R4 is C1-6alkyl, heterocyclyl, R5(R6)N- or protective group; R5 and R6, each independently represents hydrogen or C1-6alkyl or together form heterocyclyl; in addition, when R3 is C1-6alkyl, and R4, which modifies R3, namely R5 or R6, contained in R5(R6)N-, are C1-6alkyl, R3 and R5 or R6 can together form 3–7-member saturated ring; with subsequent, in case when side chain R3ONHC(=O)- has a protective group, removing the protective acid group, and depositing the crude product by adding a weak solvent to the reaction solution to obtain a crude compound of formula (VII-CR), where R3 is C1-6alkyl or heterocyclyl, R3 can be modified 0–5 R4; R4 can be successively substituted, wherein R4 is C1-6alkyl, heterocyclyl or R5(R6)N-; R5 and R6, each independently represents hydrogen or C1-6alkyl or together form heterocyclyl; in addition, when R3 is C1-6alkyl, and R4, which modifies R3, namely R5 or R6, contained in R5(R6)N-, are C1-6alkyl, R3 and R5 or R6 can together form 3–7-member saturated ring; followed by alternate addition of crude compound of formulas (VII-CR), and ice-cooled buffer to obtain a solution having pH from 4 to 5.5, by concentration after demineralisation with a synthetic adsorbent, if necessary, controlling temperature, adding the starch, if necessary, and crystallisation by adding a weak solvent to obtain a compound represented by the following formula (VII), where R3 is C1-6alkyl or heterocyclyl, R3 can be modified 0–5 R4; R4 can be successively substituted, wherein R4 is C1-6alkyl, heterocyclyl or R5(R6)N-; R5 and R6, each independently represents hydrogen or C1-6alkyl or together form heterocyclyl; in addition, when R3 is C1-6alkyl, and R4, which modifies R3, namely R5 or R6, contained in R5(R6)N-, are C1-6alkyl, R3 and R5 or R6 can together form 3–7-member saturated ring; (in each of said formulas heterocyclyl means 3–7-member monocyclic heterocyclic saturated ring or non-aromatic ring, having total of 1–3 heteroatoms selected from a nitrogen atom, an oxygen atom and a sulfur atom, as ring components).
EFFECT: disclosed method increases stability of maintaining high quality (according to HPLC) and output of intermediate and target products during storage and increase in reaction time, which enables use of the method in large-scale production.
11 cl, 4 dwg, 12 tbl, 13 ex
Title | Year | Author | Number |
---|---|---|---|
CRYSTALLINE FORMS OF DIAZABICLOCTANE DERIVATIVE AND A METHOD OF THEIR PRODUCTION | 2014 |
|
RU2801220C2 |
METHOD OF PRODUCING A DIAZABICYCLOOCTANE DERIVATIVE AND INTERMEDIATE THEREOF | 2014 |
|
RU2719480C2 |
NOVEL BETA-LACTAMASE INHIBITOR AND METHOD FOR PRODUCTION THEREOF | 2013 |
|
RU2693898C2 |
NEW β-LACTAMASE INHIBITOR AND A METHOD OF ITS PRODUCTION | 2019 |
|
RU2800050C2 |
OPTICALLY ACTIVE DIAZABICYCLOOCTANE DERIVATIVE AND METHOD FOR PRODUCTION THEREOF | 2011 |
|
RU2591701C2 |
BETA-LACTAMASE INHIBITORS | 2009 |
|
RU2445314C9 |
(2S,5R)-5-[(BENZYLOXY)AMINO]PIPERIDINE-2-CARBOXAMIDE | 2012 |
|
RU2610091C2 |
METHOD OF PRODUCING HETEROCYCLIC COMPOUNDS, INCLUDING TRANS-7-OXO-6-(SULPHOXY)-1,6-DIAZABICYCLO[3.2.1]OCTANE-2-CARBOXAMIDE AND ITS SALT | 2012 |
|
RU2769076C2 |
SIMPLE METHOD OF PRODUCING AVIBACTAM | 2018 |
|
RU2711358C1 |
METHOD OF PRODUCING CHIRAL DERIVATIVES OF TERT-BUTYL 4-((1R,2S,5R)-6-(BENZYLOXY)-7-OXO-1,6-DIAZABICYCLO[3.2.1]OCTANE-2-CARBOXAMIDO)PIPERIDINE-1-CARBOXYLATE | 2014 |
|
RU2689339C2 |
Authors
Dates
2019-07-22—Published
2014-10-08—Filed